The presentation will provide a company overview and program update, with a focus on lead immuno-oncology product, Toca 511 & Toca FC, and the Toca 5 pivotal study in patients with recurrent glioblastoma or anaplastic astrocytoma, which the company plans to start enrolling this year.
Tocagen is a clinical-stage biopharmaceutical company pursuing the discovery, development and commercialization of products built upon a broadly applicable, highly cancer-selective immuno-oncology platform. The company’s lead combination product, Toca 511 & Toca FC, is advancing into a pivotal Phase 2/3 study in 2015 for patients with recurrent glioblastoma or anaplastic astrocytoma. The FDA has granted Toca 511 & Toca FC Fast Track and orphan drug designations for the treatment of recurrent high grade glioma and glioblastoma, respectively. A study evaluating Toca 511 & Toca FC in five additional metastatic solid tumor indications is planned for 2016.
Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about ongoing clinical trials please visit www.clinicaltrials.gov using the search identifiers NCT01470794, NCT01156584, NCT01985256, or NCT02414165. For more information about Tocagen please visit www.tocagen.com or follow @Tocagen.